cb1
b4f
fa4
d70
ab3
d5f
a6f
d0d
cd4
cd4
a79
d89
b1c
d5f
a7a
f33
afb
d70
d46
fd0
cb1
afb
b8e
b8e
d70
ab3
d5f
a7a
b4f
e8a
afb
24781527
PubMed
Erlotinib in African Americans with advanced non-small cell lung cancer: a prospective randomized study with genetic and pharmacokinetic analyses.
Clin Pharmacol Ther
2014
Phelps MA
Stinchcombe TE
Blachly JS
Zhao W
Schaaf LJ
Starrett SL
Wei L
Poi M
Wang D
Papp A
Aimiuwu J
Gao Y
Li J
Otterson GA
Hicks WJ
Socinski MA
Villalona-Calero MA
16381666
PubMed
Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers.
Drug Metab Dispos
2006
Ling J
Johnson KA
Miao Z
Rakhit A
Pantze MP
Hamilton M
Lum BL
Prakash C
30105461
PubMed
In vitro UGT1A1 inhibition by tyrosine kinase inhibitors and association with drug-induced hyperbilirubinemia.
Cancer Chemother Pharmacol
2018
Qosa H
Avaritt BR
Hartman NR
Volpe DA
22594511
PubMed
Pharmacogenetics of EGFR in lung cancer: perspectives and clinical applications.
Pharmacogenomics
2012
Mayo C
Bertran-Alamillo J
Molina-Vila MÁ
Giménez-Capitán A
Costa C
Rosell R
18006847
PubMed
Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Cancer Res
2007
Shi Z
Peng XX
Kim IW
Shukla S
Si QS
Robey RW
Bates SE
Shen T
Ashby CR Jr
Fu LW
Ambudkar SV
Chen ZS
19493273
PubMed
Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib.
Cancer Sci
2009
Noguchi K
Kawahara H
Kaji A
Katayama K
Mitsuhashi J
Sugimoto Y
26820683
PubMed
Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash.
Eur J Cancer
2016
Steffens M
Paul T
Hichert V
Scholl C
von Mallek D
Stelzer C
Sörgel F
Reiser B
Schumann C
Rüdiger S
Boeck S
Heinemann V
Kächele V
Seufferlein T
Stingl J
16166415
PubMed
Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
Clin Cancer Res
2005
Johnson JR
Cohen M
Sridhara R
Chen YF
Williams GM
Duan J
Gobburu J
Booth B
Benson K
Leighton J
Hsieh LS
Chidambaram N
Zimmerman P
Pazdur R
17312388
PubMed
Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients.
Cancer Biol Ther
2007
Li J
Cusatis G
Brahmer J
Sparreboom A
Robey RW
Bates SE
Hidalgo M
Baker SD
11432895
PubMed
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.
J Clin Oncol
2001
Hidalgo M
Siu LL
Nemunaitis J
Rizzo J
Hammond LA
Takimoto C
Eckhardt SG
Tolcher A
Britten CD
Denis L
Ferrante K
Von Hoff DD
Silberman S
Rowinsky EK
16490804
PubMed
Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects.
J Clin Pharmacol
2006
Frohna P
Lu J
Eppler S
Hamilton M
Wolf J
Rakhit A
Ling J
Kenkare-Mitra SR
Lum BL
19850672
PubMed
Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases.
Drug Metab Dispos
2010
Liu Y
Ram??rez J
House L
Ratain MJ
20580994
PubMed
The UGT1A1*28 polymorphism correlates with erlotinib's effect on SN-38 glucuronidation.
Eur J Cancer
2010
Liu Y
Ram??rez J
House L
Ratain MJ
19733976
PubMed
Clinical pharmacokinetics of tyrosine kinase inhibitors.
Cancer Treat Rev
2009
van Erp NP
Gelderblom H
Guchelaar HJ
17575239
PubMed
Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes.
Clin Cancer Res
2007
Li J
Zhao M
He P
Hidalgo M
Baker SD
15155841
PubMed
High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter.
Mol Pharmacol
2004
Ozvegy-Laczka C
Hegedus T
V??rady G
Ujhelly O
Schuetz JD
V??radi A
K??ri G
Orfi L
N??met K
Sarkadi B
23022519
PubMed
Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients?
Cancer Treat Rev
2013
Rossi A
Pasquale R
Esposito C
Normanno N
28444958
PubMed
Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment.
Basic Clin Pharmacol Toxicol
2017
Parra-Guillen ZP
Berger PB
Haschke M
Donzelli M
Winogradova D
Pfister B
Früh M
Gillessen S
Krähenbühl S
Kloft C
Joerger M
16890575
PubMed
Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer.
Clin Pharmacol Ther
2006
Lu JF
Eppler SM
Wolf J
Hamilton M
Rakhit A
Bruno R
Lum BL